Skip to Content

VP-102 FDA Approval Status

Last updated by Judith Stewart, BPharm on Dec 9, 2019.

FDA Approved: No
Brand name: VP-102
Generic name: cantharidin
Dosage form: Topical Solution
Company: Verrica Pharmaceuticals Inc.
Treatment for: Molluscum Contagiosum

VP-102 (cantharidin) is a topical terpenoid in development for the treatment of molluscum contagiosum.

Development Timeline for VP-102

DateArticle
May 28, 2021Verrica Pharmaceuticals Announces Extension of FDA Review Period of its NDA for VP-102 for the Treatment of Molluscum Contagiosum
Dec 23, 2020Verrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum
Dec 23, 2020Verrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum
Jul 14, 2020Verrica Pharmaceuticals Receives Complete Response Letter from the FDA for its New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum
Jun 29, 2020Verrica Pharmaceuticals Provides Regulatory Update on VP-102
Nov 27, 2019Verrica Pharmaceuticals Announces FDA Filing Acceptance of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum
Sep 16, 2019Verrica Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for VP-102 for the Treatment of Molluscum Contagiosum
Jan  3, 2019Verrica Achieves Positive Topline Results from Two Pivotal Phase 3 Clinical Trials of VP-102 in Patients with Molluscum Contagiosum

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.